Skip to content

To explore the distribution characteristics of non renin dependent aldosterone production syndrome in hypertensive patients and the response to spironolactone treatment

To explore the distribution characteristics of non renin dependent aldosterone production syndrome in hypertensive patients and the response to spironolactone treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119124
Enrollment
Unknown
Registered
2026-02-23
Start date
2023-05-19
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Gold Standard:1.Salt water load test 2.Captopril inhibition test 3.Response to spironolactone treatment
Index test:1.24-hour urinary aldosterone measured by Chemiluminescence 2.24-hour urinary aldosterone measured by liquid chromatography / tandem mass spectrometry

Sponsors

Beijing Haidian Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Be aged between 18 and 80; 2.Patients with diagnosed hypertension who are taking medication or newly diagnosed with hypertension; 3.Screening high-risk patients with primary aldosteronism using chemiluminescence method: renin concentration 5ng/dL or aldosterone/renin>=3.7; 4.Agree to be enrolled for examination and evaluation;

Exclusion criteria

Exclusion criteria: 1.Acute and chronic renal insufficiency: eGFR 25ng/dl (considered as the possibility of unilateral disease is high, excluded); 3.oral spironolactone, sodium channel blockers such as class I antiarrhythmic drugs, potassium sparing diuretics such as amphetamine, liquorice extract, potassium excreting diuretics, and oral contraceptives containing hormone therapy such as estrogen; 4.acute stage of serious cardiovascular and cerebrovascular diseases: acute coronary syndrome, acute heart failure, new cerebral hemorrhage, new cerebral infarction, etc; 5.malignant tumor; 6.pregnancy or preparation for pregnancy during the study; 7.do not sign the informed consent form and do not want to be followed up for 3 months; 8.other conditions that cannot cooperate with the examination and treatment (such as disability, dementia, mental illness, etc.);

Design outcomes

Primary

MeasureTime frame
24-hour urinary aldosterone measured by Chemiluminescence;24-hour urinary aldosterone measured by liquid chromatography / tandem mass spectrometry;Sitting aldosterone levels before and after saline loading test;Aldosterone levels before and after captopril test;Accuracy;

Secondary

MeasureTime frame
Sensitivity;Specificity;

Countries

China

Contacts

Public ContactLin Zhou

Beijing Haidian Hospital

13521821941@163.com+86 10 8269 3140

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026